← Back to Clinical Trials
Recruiting NCT06184464
Prostatic Size Reduction Following of Leuprorelin Acetate
Trial Parameters
Condition Prostate Cancer Adenocarcinoma
Sponsor Consorci Sanitari de Terrassa
Study Type OBSERVATIONAL
Phase N/A
Enrollment 40
Sex MALE
Min Age 18 Years
Max Age 95 Years
Start Date 2024-02-02
Completion 2024-12-15
All Conditions
Interventions
ACETATE LEUPRELINE
Brief Summary
To determine the possible reduction in prostate size following the administration of Leuprelin prior to the application of radiotherapy.
Eligibility Criteria
Inclusion Criteria: Man with Prostate positive biopsy. Able to Ssgned informed consent form. Need of hormonal treatment before start of radiotherapy Exclusion Criteria: Patients With prostate size of less than 20 cc at diagnosis. Patients With Positive lymph nodes or metastatic prostate cancer disease on imaging studies. Patients with Previous pelvic radiation therapy.
Related Trials
NCT07182279
Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Ca
View Trial →
NCT07179783
Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Pros
View Trial →
NCT06184464
Prostatic Size Reduction Following of Leuprorelin Acetate
View Trial →